International Stroke Conference 2025  /  Large Vessel Disease from Arteries to Veins (Non-Acute Treatment) Oral Abstracts  /  Evolocumab added to statin is superior to statin alone in reversing symptomatic intracranial atherosclerotic stenosis
Logo

American Heart Association

  130
  0

Final ID: 38

Evolocumab added to statin is superior to statin alone in reversing symptomatic intracranial atherosclerotic stenosis

Abstract Body: Background and Purpose: We aimed to investigate the effects of evolocumab, a proprotein convertase subtilisin/kexin type-9 inhibitor for intensive lipid-lowering, on intracranial atherosclerotic stenosis (ICAS).
Methods: From a prospectively established high-resolution magnetic resonance imaging (HR-MRI) database, consecutive ICAS (>50%) patients with two detections of HR-MRI over six months were included in this study. The patients were divided into two groups: those with (evolucomab+) or without (evolocumab-) evolocumab add-on therapy. The primary outcomes were the percentage change in plaque burden and plaque response (plaque regression >5%) rate. The second outcome was the percentage change in stenosis degree. Cox regression analysis was used to estimate the association between evolocumab add-on therapy and the above outcomes in both general and subgroup (intensive statin vs. non-intensive statin) analysis.
Results: The data of 179 patients receiving statins and/or ezetimibe, 50 of which with evolucumab and 129 without, were analyzed. Evolocumab add-on therapy over six months showed a significant reduction in the percentage change of plaque burden (evolocumab+, median [IQR]: 0.08 [0.02-0.11] vs. evolocumab-: 0.02 [0.04-0.07]), increase in plague response rate (evolocumab+: 68.0% vs. evolocumab-: 34.1%), and reduction in the percentage change of stenosis degree (evolocumab+: 0.15 [0.01-0.34] vs. evolucumab-: 0.05 [-0.12-0.26]). After adjusting for potential confounders, evolocumab was significantly associated with the percentage reduction in plaque burden (estimate [95% CI], 0.074 [0.029-0.119]), the increase in plague response rate (6.70 [2.81-16.99]), and the percentage reduction in stenosis degree (0.198 [0.074-0.321]). In both intensive and non-intensive statin groups, evolocumab add-on therapy was still significantly associated with better outcomes in the percentage reduction in plague burden (intensive: 0.063 [0.004-0.121], P < 0.05; non-intensive: 0.126 [0.045-0.208], P < 0.01), the increase in plaque response rate (intensive: 3.75 [1.09-14.10], P < 0.05; non-intensive: 11.60 [2.55 – 52.82], P < 0.01), and the percentage reduction in stenosis degree (intensive: 0.148 [-0.015-0.312], P = 0.075; non-intensive: 0.331 [0.118-0.544], P < 0.01).
Conclusions: Evolocumab add-on therapy over six months is superior to statin alone in reversing symptomatic ICAS.
  • Liu, Yiyang  ( Peking Union Medical College Hospital , Beijing , China )
  • Hu, Xinzhi  ( Peking Union Medical College Hospital , Beijing , China )
  • Yuan, Weizhuang  ( Peking Union Medical College Hospital , Beijing , China )
  • Li, Shun  ( Peking Union Medical College Hospital , Beijing , China )
  • Zhang, Yuelun  ( Peking Union Medical College Hospital , Beijing , China )
  • Li, Mingli  ( Peking Union Medical College Hospital , Beijing , China )
  • Xu, Yan  ( Peking Union Medical College Hospital , Beijing , China )
  • Xu, Wei-hai  ( Peking Union Medical College Hospital , Beijing , China )
    • Author Disclosures:
    Yiyang Liu: DO NOT have relevant financial relationships | Xinzhi Hu: No Answer | Weizhuang Yuan: DO NOT have relevant financial relationships | Shun Li: No Answer | Yuelun Zhang: No Answer | Mingli Li: DO NOT have relevant financial relationships | Yan Xu: No Answer | Wei-hai Xu: No Answer
Meeting Info:

International Stroke Conference 2025

2025

Los Angeles, CA

Session Info:

Large Vessel Disease from Arteries to Veins (Non-Acute Treatment) Oral Abstracts

Wednesday, 02/05/2025 , 09:15AM - 10:45AM

Oral Abstract Session

More abstracts on this topic:
Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial

Bohula Erin, Wang Huei, Cyrille Marcoli, Paiva Da Silva Lima Gabriel, Giugliano Robert, Sabatine Marc, Marston Nicholas, Bhatia Ajay, De Ferrari Gaetano Maria, Leiter Lawrence, Nicolau Jose, Park Jeong-gun, Murphy Sabina, Walsh Emileigh

Clinical characteristics and treatment of high-risk cardiovascular patients without prior myocardial infarction or stroke: VESALIUS-REAL - results from US

Chan Queenie, Jernberg Tomas, Cegla Jaimini, Budoff Matthew, Wong Ian, Sakhuja Swati, Ochs Andreas, Dhalwani Nafeesa, O'kelly James, Shannon Erin, Paivadasilva Lima Gabriel, Avcil Suna, Laufs Ulrich

More abstracts from these authors:
Nighttime Blood Pressure and Intracranial Atherosclerotic Stenosis: Dose-Response Associations With Atherosclerotic Burden and Symptomatic Status

Zhou Huanyu, Xu Yan, Liu Caiyan, Xu Wei-hai, Zou Yinxi, Cheng An-qi, Liu Yiyang, Liu Niyuan, Guo Haoyao, Li Mingli, Wang Yining, Zhang Yuelun

Deep tiny flow voids on high-resolution magnetic resonance imaging predict a favorable prognosis in patients with acute middle cerebral artery occlusion

Ding Manqiu, Yuan Weizhuang, Li Mingli, Xu Yan, Xu Wei-hai

4171983_File000000.jpg
4171983_File000000.jpg
4171983_File000001.jpg
4171983_File000001.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.

   Rate this abstract  (Maximum characters: 500)